Idexx Laboratories INC /DE 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
IDEXX Laboratories announced a robust first quarter for 2026, with significant revenue growth driven by its Companion Animal Group and improved profitability.
NASDAQ
IDEXX Laboratories reports robust third-quarter 2025 financial results, driven by significant growth in companion animal diagnostics and improved profitability.
NASDAQ
IDEXX Laboratories reports robust Q2 2025 financial results with significant revenue and earnings per share growth, driven by strong performance in its Companion Animal Group.
NASDAQ
IDEXX Laboratories' Q1 2025 results show revenue and earnings growth, primarily driven by the Companion Animal Group, with a focus on recurring diagnostic revenue.
NASDAQ
IDEXX Laboratories reports a 6.1% organic revenue growth in Q3, driven by strong performance in its Companion Animal Group, while managing macroeconomic challenges.
NASDAQ
IDEXX Laboratories' second-quarter results show revenue growth offset by a significant litigation expense, impacting overall profitability.
NASDAQ
IDEXX Laboratories saw a 7.1% increase in revenue in Q1 2024, driven by strong performance in its Companion Animal Group.